← All trials
NCT04060511
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2019
- Primary completion
- Dec 31, 2019
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.